ONO-4053 clinical trials
Also written ONO-4053.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How each study uses ONO-4053 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ONO-4053
- 2
Studies by the year they started
4 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses ONO-4053 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Phase II Study Evaluating ONO-4053 and Cetirizine in Subjects With Seasonal Allergic RhinitisCompletedPhase 2Ono Pharmaceutical Co. LtdNCT01748344Written as High dose ONO-4053How we know
- A Human Mass Balance Study to Determine the Total Recovery of Radioactivity in Urine and Faeces Following a Single Oral Dose of 14C Radiolabelled ONO-4053CompletedPhase 1Ono Pharmaceutical Co. LtdNCT01909986Written as [14C]ONO-4053How we know
- A Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of ONO-4053 in Healthy VolunteersCompletedPhase 1Ono Pharmaceutical Co. LtdNCT01537172Written as ONO-4053How we know
- A Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of ONO-4053 in Healthy VolunteersTerminatedPhase 1Ono Pharmaceutical Co. LtdNCT01379586Written as ONO-4053How we know